• Size of pulmonary embolus (PE) at the time of recurrence compared with first event is unstudied.
Summary. Background: The size of recurrent pulmonary embolus (PE) in relation to a prior event could be a factor in deciding whether to continue anticoagulation. There are no published data on this subject to help with counselling patients. Objectives: To determine whether size of a first PE predicts the size at recurrence. Patients and methods: This was a retrospective cohort study of consecutive patients with recurrent PE over 25 months at a single tertiary center. In confirmed cases the sizes of first and recurrent PEs were grouped into radiologically non-massive PE (RNMPE) or radiologically massive PE (RMPE) if there was bilateral main pulmonary artery thrombus, saddle PE or right ventricular strain on the computerized tomography pulmonary angiogram. Results: Sixty-three patients were included in the study (37 exclusions). Thirty-seven patients were men and 26 women, with a median age of 72 years; 33.3% of PEs were unprovoked. Patients whose first PE was an RNMPE (46/63 or 73% of patients) had a 15.2% (95% confidence interval [CI], 7.6-28.2%) chance of RMPE at recurrence and a 32.6% (95% CI 20.9-47.0%) chance of having a larger PE at recurrence, whereas those who presented first with an RMPE (17/63 or 27% or patients) had a 17.6% (95% CI, 6.2-41.0%) chance of RMPE at recurrence (odds ratio, 1.19; CI, 0.27-5.27). Conclusions: Risk of a massive PE at recurrence is low (and similar) irrespective of the size of the first PE in this single study. Further studies are warranted as this could help in decisions on long-term anticoagulation.
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Introduction
Patients with an unprovoked venous thromboembolism (VTE) are at a much higher risk of recurrence compared with those with provoked VTE [1] . The optimal duration of anticoagulation for patients with an unprovoked pulmonary embolism (PE) is uncertain. Recommendations for length of anticoagulant therapy after a PE are 3 months (or 6 months for cancer), followed by assessment of the risk-benefit balance of continuing anticoagulation [2, 3] . From a systematic review of seven studies involving 1888 patients with first unprovoked PE it is known that a raised D-dimer after stopping anticoagulant therapy is predictive of the risk of PE recurrence [4] . There are currently three different clinical tools/models that try and predict risk of recurrence for patients using clinical data such as the D-dimer, the HERDOO2 score, the Vienna prediction model and the DASH score [5] [6] [7] . These are not yet fully validated in prospective trials. As far as we know, no study has addressed whether the size of a first PE correlates with size of PE at recurrence. If a correlation were to be found, then this could be used, along with the current risk prediction tools, to more individually assess the risk-benefit of continued anticoagulation for each patient. Our objective was to determine, through a retrospective cohort of patients with recurrent PE, whether the size of a first PE predicted size at recurrence.
Methods
Cambridge University Hospital National Health Service Foundation Trust maintains a prospective database of all patients presenting with venous thromboembolic disease. This database was retrospectively used to examine the electronic patient record (EPIC, Epic systems Corp, Verona, WI, USA) of every patient with a PE, between 1 November 2014 and 30 November 2016 (n = 857), to identify patients with a recurrent PE (n = 100). Patients were excluded if (i) historic results were unavailable (e.g. CT scan performed at another hospital), (ii) patients were on anticoagulation at the time of the recurrent PE and (iii) CT pulmonary angiograms were not performed to diagnose PE (i.e. VQ scan was used). Patient demographics and clinical information were extracted from the electronic patient record. Records of previous computerized tomography pulmonary angiogram (CTPA) results were extracted from the picture archive communicating system (PACS, Centricity Enterprise Web v3.0, GE Healthcare, Chicago, IL, USA). The size and extent of the PE was then classified (Table 1 ). Category 1-4 patients have been termed 'radiologically non-massive PE' (RNMPE) and category 5-6 patients 'radiologically massive PE' (RMPE). For patients with more than two PEs the last two events were used to compare recurrence severity (as at least one of these events fell within the identified study period). The size of the PE was compared between the recurrent events. Two independent investigators extracted the data and any areas of uncertainty were resolved by consensus or obtaining further information about the patient. Patients with chronic thrombosis on CTPA with no radiological evidence of new PE were not included in the study. The results were analysed using odds ratio (OR) with confidence intervals (CIs) set at 95%, with the aim of proving that 'the chance of having an RMPE at recurrence is affected by the size of first PE'. The Wilson method was used to calculate confidence intervals.
Results and discussion
In total, 857 patients had a confirmed PE at the hospital in the study period 1 November 2014 to 30 November 2016. One hundred cases of recurrent PE were identified during the study period. Thirty-seven cases were excluded for a variety of reasons (Fig. 1) . The characteristics of the remaining 63 patients included in the study are outlined in Table 2 . For patients with provoked PE, risk factors included malignancy (27.6%), surgery (17.2%), hospital admission (15.5%), immobilization (6.9%) or hormones (combined oral contraceptive pill or pregnancy) (3.4%), 22.5% cases had a variety of other causes (e.g. inflammation or other minor provoking factors) and in 6.9% of cases the provoking factor was not obtainable from the medical record.
Patients whose first PE was an RNMPE (46/63 or 73% of patients) had a 15.2% (95% CI, 7.6-28.2%) chance of RMPE at recurrence and a 32.6% (95% CI, 20.9-47.0%) chance of having a larger PE at recurrence, whereas those who presented first with an RMPE (17/63 or 27% or patients) had a 17.6% (95% CI, 6.2-41.0%) chance of RMPE at recurrence (OR, 1.19; 95% CI, 0.27-5.27; P = 0.81). The results are summarized in Table 3 .
Currently the size or severity of an unprovoked first PE does not feature within risk recurrence prediction models or guidance for treatment of PE [2, 3, [5] [6] [7] . From these studies, the determination of probability of recurrent PE is possible but not what the size or severity of recurrence will be. Intuitively if a patient has a large unprovoked PE then there may be an inclination to continue long-term anticoagulation so as not to risk another large event, as it is known that PE with circulatory instability confers a high mortality [8, 9] . Massive PE with cardiogenic shock can be successfully treated with thrombolysis but this carries risk of major hemorrhage so clinicians and patients alike are keen to avoid this situation if there is PE recurrence [10] . The results presented here show that the risk of an RMPE at recurrence for the entire cohort of patients was 15.9% (15.2% for patients with first RNMPE and 17.6% for first RMPE), which is low and would not justify, in isolation, long-term anticoagulation, as the balance of probability means that recurrence will be RNMPE. These results would also suggest that the radiological size of the first PE does not predict size at recurrence. This study has several important limitations and its findings should be interpreted cautiously. First, it is a small retrospective cohort study that may be prone to bias. A strong source of bias will be that patients with PE (such as first large unprovoked PE) may continue uninterrupted on anticoagulation. This means they will not be subject to recurrence and therefore not included in this retrospective study for analysis. Second, there were a large number of patients who were not included in the study as records were not available from other institutions or the PE was too long ago to obtain records. Third, this study contains a mixture of patients with provoked and unprovoked PE who are a relatively old population. These are quite different populations with different pathologies and therefore trying to generalize the data to individual (perhaps younger) patients may be difficult. Fourth, we have not used a clinical score such as the pulmonary severity index (PESI) or outcome (including death) to determine the severity of recurrent PE [11] . Fifth, the RV strain may have other causes than PE (thereby upgrading some patients with PE to the radiologically massive category) and we do not have a CTPA to show residual clot burden after the first PE, and therefore thrombosis at recurrence may be chronic from the index event. In answer to these limitations, radiologists at our institution usually comment on a PE causing an acute RV strain and also differentiate between acute and chronic thrombosis seen on CTPA. Lastly, a recognized system for quantifying the size of PE was not used although scores have been published; however, their clinical relevance is debated [12] . In the real world it is unlikely that radiologists would start reporting all CTPAs with a formal clot burden score. Instead, clinicians need a quick answer regarding the size of PE and also whether there is RV strain (which is critical information). We therefore focused on extracting this relevant information from the radiology reports. Multiple sub-segmental PEs may have a higher overall clot burden than a single central PE and therefore future studies could address this issue; our focus, however, was to try and identify massive PEs that would probably have endpoints that are clinically significant, such as death, morbidity or needing thrombolysis.
Patient preference is an important factor in continuing anticoagulation after 3 months of initial treatment for a VTE. Patients with a large VTE at first presentation may be keen to avoid a further thrombosis because of the severity of the initial event (including morbidity and hospitalization). Patient choice, and their attitude to risk, will therefore remain a key part of duration of anticoagulation. This study has limitations but it suggests the size of recurrent PE is not influenced by the size of the index event and rates of massive PE at recurrence may be low (around 15%, although this needs further investigation). Currently, the size of an initial PE is not formally part of risk prediction models for recurrent PE but patients and physicians may still, informally at least, discuss this in clinic when deciding on anticoagulation as part of the counselling process for treatment duration [5] [6] [7] . The result of our study justifies further prospective studies with formalized protocols and larger numbers of patients to determine whether the size (and also clinical severity) of the initial PE should have an impact on long-term anticoagulation, based upon the risks of recurrence.
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